Suppr超能文献

相关综合征

Associated Syndrome

作者信息

Zarate Yuri A, Bosanko Katherine, Fish Jennifer

机构信息

Section of Genetics and Metabolism, University of Arkansas for Medical Sciences, Little Rock, Arkansas

Division of Genetics and Metabolism, University of Kentucky, Lexington, Kentucky

Abstract

CLINICAL CHARACTERISTICS

-associated syndrome (SAS) is a multisystem disorder in which all affected individuals have developmental delay / intellectual disability that can range from mild to profound but is most commonly moderate to profound. Speech delay and/or absent speech is observed in all affected individuals. Other neurobehavioral manifestations can include jovial or friendly personality, autistic tendencies, agitation or aggressive outbursts, self-injury, impulsivity, hyperactivity, anxiety, difficulty falling asleep or maintaining sleep, and sensory issues. Most affected individuals have hypotonia. EEG abnormalities are frequent but may be without clinically recognizable seizures. While only about 20% of affected individuals have clinical seizures, a subset of affected individuals have electrical status epilepticus in sleep. Craniofacial findings can include nonspecific dysmorphic features, palatal anomalies (cleft palate, high-arched palate, velopharyngeal insufficiency, bifid uvula), and dental anomalies (abnormal shape or size or the upper central incisors, dental crowding, hypodontia, and delayed teeth eruption, among others). Skeletal anomalies can include scoliosis, tibial bowing, and joint contractures. At least one third of individuals have a history of previous fractures and about one quarter of affected individuals have documented low bone mineral density. Other finding can include pre- and postnatal growth restriction, feeding issues, and eye anomalies (strabismus, refractive error). In those with a larger deletion involving and adjacent genes, cardiovascular, genitourinary, and ectodermal findings may also be present.

DIAGNOSIS/TESTING: The diagnosis of SAS is established in a proband with suggestive findings and identification of one of the following by molecular genetic testing: a heterozygous intragenic pathogenic variant; a heterozygous non-recurrent deletion at 2q33.1 that includes ; a chromosome translocation or inversion with a 2q33.1 breakpoint that disrupts ; a chromosomal duplication with breakpoints that encompass

MANAGEMENT

Standard treatment for developmental delay / intellectual disability, neurobehavioral issues, cleft palate, micrognathia, dental anomalies, scoliosis, tibial bowing, joint contractures, spasticity, epilepsy, undescended testes, inguinal hernia, hypospadias, refractive error, strabismus, and congenital heart defects. For those with feeding issues and/or poor weight gain, feeding therapy is typically recommended, with a low threshold for clinical feeding evaluation and/or radiographic swallowing study if there are signs or symptoms of dysphagia. A gastrostomy tube placement may be required for persistent feeding issues. Sleep disturbance may respond to sleep hygiene healthy habits and potential medical management, as needed. In those with restless sleep, an overnight EEG to explore potential epileptogenic abnormalities may be considered. To address osteopenia / frequent fractures, optimize physical activity and calcium / vitamin D levels; denosumab and bisphosphonates have also been used with no direct comparison between the different options. At each visit, measure growth parameters, nutrition status, and safety of oral intake; assess for new manifestations, such as seizures or changes in tone; monitor developmental progress and educational needs; assess for anxiety, ADHD, ASD, aggression, & self-injury; evaluate for scoliosis and spine deformities; and assess for signs/symptoms of sleep disturbance. At least annually, dental evaluation with consideration of orthodontics; ophthalmology evaluation; obtain a DXA scan for bone mineral density if z score is below −1; measure alkaline phosphatase level (if previously elevated). Every two years, obtain a DXA scan for bone mineral density if z score is above −1; measure alkaline phosphatase level (if previously normal).

GENETIC COUNSELING

SAS is an autosomal dominant disorder. Almost all probands with SAS reported to date have the disorder as the result of a genetic event. In approximately 1% of affected individuals, SAS is the result of a genetic alteration inherited from a mosaic parent. To date, individuals with SAS are not known to reproduce. Once the genetic alteration has been identified in an affected family member, prenatal and preimplantation genetic testing are possible.

摘要

临床特征

相关综合征(SAS)是一种多系统疾病,所有受影响个体均有发育迟缓/智力残疾,程度可从轻度到重度,但最常见的是中度到重度。所有受影响个体均观察到语言发育迟缓或无语言能力。其他神经行为表现可包括性格开朗或友善、自闭症倾向、烦躁或攻击性爆发、自我伤害、冲动、多动、焦虑、入睡困难或维持睡眠困难以及感觉问题。大多数受影响个体有肌张力减退。脑电图异常很常见,但可能无临床可识别的癫痫发作。虽然只有约20%的受影响个体有临床癫痫发作,但一部分受影响个体在睡眠中有电持续状态癫痫。颅面表现可包括非特异性畸形特征、腭部异常(腭裂、高拱腭、腭咽闭合不全、悬雍垂裂)和牙齿异常(上中切牙形状或大小异常、牙列拥挤、缺牙、牙齿萌出延迟等)。骨骼异常可包括脊柱侧弯、胫骨弓形弯曲和关节挛缩。至少三分之一的个体有既往骨折史,约四分之一的受影响个体有记录的低骨矿物质密度。其他表现可包括产前和产后生长受限、喂养问题和眼部异常(斜视、屈光不正)。在涉及 和相邻基因的较大缺失的个体中,也可能出现心血管、泌尿生殖系统和外胚层表现。

诊断/检测:SAS的诊断在具有提示性发现的先证者中确立,并通过分子遗传学检测鉴定以下之一:杂合子基因内 致病变异;2q33.1处的杂合子非复发性缺失,包括 ;具有破坏 的2q33.1断点的染色体易位或倒位;具有包含 的断点的染色体重复

管理

针对发育迟缓/智力残疾、神经行为问题、腭裂、小颌畸形、牙齿异常、脊柱侧弯、胫骨弓形弯曲、关节挛缩、痉挛、癫痫、隐睾、腹股沟疝、尿道下裂、屈光不正、斜视和先天性心脏缺陷的标准治疗。对于有喂养问题和/或体重增加不佳的个体,通常建议进行喂养治疗,如果有吞咽困难的体征或症状,则临床喂养评估和/或放射学吞咽研究的阈值较低。对于持续的喂养问题,可能需要放置胃造瘘管。睡眠障碍可能对睡眠卫生健康习惯和必要时的潜在药物治疗有反应。对于睡眠不安的个体,可考虑进行夜间脑电图检查以探索潜在的致痫异常。为解决骨质减少/频繁骨折问题,优化体育活动和钙/维生素D水平;地诺单抗和双膦酸盐也已使用,但不同选项之间没有直接比较。每次就诊时,测量生长参数、营养状况和口服摄入的安全性;评估新的表现,如癫痫发作或肌张力变化;监测发育进展和教育需求;评估焦虑、注意力缺陷多动障碍、自闭症谱系障碍、攻击性和自我伤害;评估脊柱侧弯和脊柱畸形;并评估睡眠障碍的体征/症状。至少每年进行一次牙科评估并考虑正畸治疗;眼科评估;如果z评分低于−1,进行骨矿物质密度的双能X线吸收法扫描;测量碱性磷酸酶水平(如果之前升高)。每两年,如果z评分高于−1,进行骨矿物质密度的双能X线吸收法扫描;测量碱性磷酸酶水平(如果之前正常)。

遗传咨询

SAS是一种常染色体显性疾病。迄今为止报告的几乎所有SAS先证者都是 基因事件导致的疾病。在大约1%的受影响个体中,SAS是从嵌合父母遗传的基因改变的结果。迄今为止,已知SAS个体不会生育。一旦在受影响的家庭成员中鉴定出基因改变,产前和植入前基因检测是可行的。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验